North America Cardiac Marker Testing Market

North America Cardiac Marker Testing Market Size (2023 to 2028):

The size of the North America Cardiac Marker Testing Market is anticipated to grow at 7.89% CAGR from 2023 to 2028. The market is expected to be valued at USD 1.20 billion in 2023 and is projected to reach USD 1.76 billion by 2028.

Growing funds and investments by different organizations to surge the research and clinical trials rise in the aging population. In 2016, the number of older people aged 65 years and above was nearly 8.5%. By the end of 2050, the count is expected to surge over 17%, according to the National Institutes of Health (NIH). The rise in the aging population is associated with increased cardiovascular diseases like cardiac failure, myocardial infarction, and angina pectoris. The rising popularity of point of care testing and the rapid development of healthcare infrastructure accelerates the growth. Also, the government and research institutes determined efforts to deal with severe cardiac diseases and growing research and development activities relevant to the market are to boost the market in the region.

Less availability of test kits and high competition among the key players in the market, the entrance for new players in the market cannot mark prints effectively are hindering the market growth in the region. The expensive nature of the tests associated with some tests' less specificity is acting as a barrier to market growth in the area.

This research report on the North America Cardiac Marker Testing Market has been segmented and sub-segmented into the following categories:

• By Type: Troponin I & T, CK-MB, Myoglobin, BNP and HsCRP
• By Product: Reagent, Instrument (Chemiluminescence, Immunofluorescence, Immunochromatography, ELISA)
• By Disease: Acute Coronary Syndrome, Myocardial Infarction and Congestive Heart Failure
• By Testing Lab and POC
• By Country: The United States, Canada & Rest of North America

Regional Analysis:

North America held the largest share of the global cardiac marker testing market. Factors such as public-private initiatives to increase awareness related to early cardiac disease diagnosis in patients and physicians and increasing knowledge about technological advancements among lab professionals and cardiologists due to ongoing conferences and seminars are the key factors aiding the growth of the markets.

The United States is ruling the market in this region based on the increasing obese population, which has become a health challenge in the last few years. Every sixth person is obese, and the number of obese people in the region has been doubled, according to WHO. 1.9 billion Adults are suffering from obesity, and over 650 were obese. Obesity is concerned with the growing number of cardiovascular diseases like congestive heart failure and more. Surging government observation in minimizing the length of the stay of the patient and different modes of patient care like an emergency room, homecare and near-patient testing and advancements in healthcare for personalized medicine has surged the significance of cardiac makers for fast, efficient, and quality maintenance of the health stimulating the market growth in the region.

Promising Companies leading the North America Cardiac Marker Testing Market Profiled in the report are Getinge Group, Medtronic plc, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd, and Guangzhou Wondfo Biotech Co. Ltd.